AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Pridinol acts centrally on the nervous system to induce muscle relaxation. It helps alleviate muscle spasms, stiffness, and tension, thereby improving mobility and reducing discomfort associated with musculoskeletal conditions.
Antispasmodic Effects: Pridinol exerts antispasmodic effects by inhibiting the excessive contraction of muscles. It is particularly useful in the treatment of conditions characterized by abnormal or involuntary muscle contractions, such as muscle spasms, cramps, and dystonia.
Pain Relief: By promoting muscle relaxation and reducing muscle spasms, pridinol can help alleviate associated pain symptoms. It may be used as an adjunctive therapy in the management of acute and chronic musculoskeletal pain conditions.
Adjunctive Therapy: Pridinol is often used as an adjunctive therapy alongside other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or physical therapy, to enhance the overall management of musculoskeletal disorders.
Safety Profile: Pridinol is generally well-tolerated when used at recommended dosages. Common side effects may include drowsiness, dizziness, dry mouth, blurred vision, and gastrointestinal disturbances. These side effects are usually mild and transient.
Central Nervous System Effects: Due to its central nervous system activity, pridinol may cause sedation or drowsiness, particularly at higher doses. Patients should be advised to avoid activities requiring mental alertness, such as driving or operating heavy machinery, until they know how the medication affects them.
Contraindications: Pridinol is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should be used with caution in patients with certain medical conditions, such as glaucoma, urinary retention, or severe hepatic or renal impairment.
Drug Interactions: Pridinol may interact with other medications that have sedative or CNS depressant effects, including alcohol, benzodiazepines, and opioids. Healthcare providers should assess potential drug interactions and adjust dosages accordingly when prescribing pridinol.
Pregnancy and Lactation: The safety of pridinol use during pregnancy and lactation has not been well-established. Pregnant or breastfeeding women should consult their healthcare provider before using pridinol.
Overdose: In cases of overdose or excessive ingestion of pridinol, symptoms may include severe CNS depression, respiratory depression, hypotension, and coma. Immediate medical attention is necessary if overdose is suspected.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
0 | 1 | Bacteroides humanifaecis | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Segatella bryantii | species | Decreases |
0 | 1 | Parabacteroides johnsonii | species | Decreases |
0 | 1 | Dysosmobacter welbionis | species | Decreases |
0 | 1 | Alistipes indistinctus | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Leyella stercorea | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
0 | 1 | Alistipes shahii | species | Decreases |
0 | 1 | Butyricimonas virosa | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Clostridium sp. M62/1 | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Alistipes communis | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
0 | 1 | Subdoligranulum variabile | species | Decreases |
0 | 1 | Clostridium sp. SY8519 | species | Decreases |
0 | 1 | Streptococcus suis | species | Decreases |
0 | 1 | Alistipes senegalensis | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 1 | 1 | |
ADHD | 1.4 | 1.4 | |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.3 | -2 |
Allergic Rhinitis (Hay Fever) | 1.2 | 0.7 | 0.71 |
Allergies | 2.2 | 1.1 | 1 |
Allergy to milk products | 0.9 | 1 | -0.11 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 3.8 | 2.6 | 0.46 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.5 | 1 |
Ankylosing spondylitis | 2.1 | 0.9 | 1.33 |
Anorexia Nervosa | 0.3 | 1.2 | -3 |
Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
Asthma | 2.1 | 0.6 | 2.5 |
Atherosclerosis | 1.9 | 0.4 | 3.75 |
Atrial fibrillation | 1.3 | 1.8 | -0.38 |
Autism | 3.4 | 4.4 | -0.29 |
Autoimmune Disease | 0.5 | 0.1 | 4 |
Barrett esophagus cancer | 0.3 | 0.1 | 2 |
benign prostatic hyperplasia | 0.4 | 0.4 | 0 |
Biofilm | 1.5 | 1.5 | |
Bipolar Disorder | 1.4 | 0.1 | 13 |
Brain Trauma | 0.1 | 0.6 | -5 |
Breast Cancer | 1.2 | 1.2 | |
Cancer (General) | 0.3 | 0.3 | |
Carcinoma | 2.3 | 0.7 | 2.29 |
Celiac Disease | 2.5 | 1 | 1.5 |
Cerebral Palsy | 0.5 | 0.6 | -0.2 |
Chronic Fatigue Syndrome | 2.1 | 2.8 | -0.33 |
Chronic Kidney Disease | 1.4 | 0.6 | 1.33 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.5 | 1.2 |
Chronic Urticaria (Hives) | 0.8 | 1 | -0.25 |
Coagulation / Micro clot triggering bacteria | 1.2 | 0.2 | 5 |
Cognitive Function | 0.7 | 0.2 | 2.5 |
Colorectal Cancer | 5 | 1.6 | 2.13 |
Constipation | 1.4 | 0.1 | 13 |
Coronary artery disease | 1.1 | 1.2 | -0.09 |
COVID-19 | 4.4 | 3.7 | 0.19 |
Crohn's Disease | 5.7 | 1.9 | 2 |
Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
cystic fibrosis | 0.8 | 0.6 | 0.33 |
d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
deep vein thrombosis | 2.2 | 0.6 | 2.67 |
Denture Wearers Oral Shifts | 0.8 | 0.8 | |
Depression | 4.8 | 2.3 | 1.09 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 1 | 0.7 | 0.43 |
Endometriosis | 1.7 | 0.6 | 1.83 |
Eosinophilic Esophagitis | 0.3 | 0.1 | 2 |
Epilepsy | 2.4 | 1.3 | 0.85 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 1 | 1.4 | -0.4 |
Functional constipation / chronic idiopathic constipation | 3.1 | 1.9 | 0.63 |
gallstone disease (gsd) | 1.8 | 0.5 | 2.6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.2 | 0.1 | 21 |
Generalized anxiety disorder | 1.9 | 0.5 | 2.8 |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.5 | 0.2 | 1.5 |
Graves' disease | 0.7 | 0.6 | 0.17 |
Gulf War Syndrome | 0.1 | 1.2 | -11 |
Halitosis | 1.5 | 0.1 | 14 |
Hashimoto's thyroiditis | 1.5 | 0.8 | 0.88 |
Heart Failure | 2.5 | 0.1 | 24 |
hemorrhagic stroke | 0.6 | 0.6 | |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
High Histamine/low DAO | 0.6 | 0.6 | |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 1 | 0.7 | 0.43 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.8 | 2.2 | -0.22 |
Hypoxia | 0.7 | 0.7 | |
IgA nephropathy (IgAN) | 1.1 | 2 | -0.82 |
Inflammatory Bowel Disease | 4.5 | 3.7 | 0.22 |
Insomnia | 0.6 | 0.6 | 0 |
Intelligence | 1.5 | 0.4 | 2.75 |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 3.4 | 2.1 | 0.62 |
ischemic stroke | 1.2 | 1 | 0.2 |
Liver Cirrhosis | 3 | 1.8 | 0.67 |
Long COVID | 2.7 | 2.1 | 0.29 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0.8 | 0.8 | |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 1.1 | 1.1 | |
ME/CFS with IBS | 0.1 | 0.5 | -4 |
ME/CFS without IBS | 0.2 | 0.9 | -3.5 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.1 | 0.1 | 0 |
Metabolic Syndrome | 3.9 | 3.4 | 0.15 |
Mood Disorders | 3.7 | 1.9 | 0.95 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
Multiple Sclerosis | 2.2 | 2.3 | -0.05 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | |
myasthenia gravis | 0.5 | 0.1 | 4 |
neuropathic pain | 0.8 | -0.8 | |
Neuropathy (all types) | 0.1 | 0.6 | -5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.6 | 2.67 |
NonCeliac Gluten Sensitivity | 0.4 | 0.4 | 0 |
Obesity | 3 | 2.7 | 0.11 |
obsessive-compulsive disorder | 3.4 | 1 | 2.4 |
Osteoarthritis | 1.5 | 0.5 | 2 |
Osteoporosis | 1 | 0.5 | 1 |
pancreatic cancer | 0.7 | 0.1 | 6 |
Parkinson's Disease | 3.1 | 3 | 0.03 |
Polycystic ovary syndrome | 3.9 | 1 | 2.9 |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
primary biliary cholangitis | 0.1 | 1 | -9 |
Primary sclerosing cholangitis | 1.2 | 0.8 | 0.5 |
Psoriasis | 1.2 | 1.5 | -0.25 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.5 | 0.87 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 2 | 0.8 | 1.5 |
scoliosis | 0.5 | 0.3 | 0.67 |
sensorineural hearing loss | 0.1 | 0.1 | |
Sjögren syndrome | 1.1 | 1.3 | -0.18 |
Sleep Apnea | 0.5 | 0.6 | -0.2 |
Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1.3 | |
Stress / posttraumatic stress disorder | 1.8 | 0.8 | 1.25 |
Systemic Lupus Erythematosus | 2.6 | 0.7 | 2.71 |
Tic Disorder | 0.7 | 0.6 | 0.17 |
Tourette syndrome | 0.1 | 0.4 | -3 |
Type 1 Diabetes | 2.4 | 1.2 | 1 |
Type 2 Diabetes | 4.4 | 4.1 | 0.07 |
Ulcerative colitis | 3.5 | 4 | -0.14 |
Unhealthy Ageing | 3.2 | 0.5 | 5.4 |
Vitiligo | 1.3 | 0.3 | 3.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]